Clinical trials: Anticoagulant
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Deep Vein Thrombosis, Pulmonary Embolism
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
The purpose of this study is to determine if the risk of recurrent venous thromboembolism (VTE) after stopping therapy is low and acceptable in patients with a first unprovoked proximal deep vein thrombosis (DVT) or pulmonary…
- Trial name
- DODS (NCT00720915)
- Testing
- Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 410 people
- Sponsor
- McMaster University
Valvular Heart Disease Patients
Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves
Warfarin is the standard anticoagulant used for patients with mechanical heart valves; however, its use is complicated by a narrow therapeutic window, frequent drug and dietary interactions, and the need for regular international…
- Trial name
- NCT07456085
- Testing
- Rivoroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Rawalpindi Institute of Cardiology
Atrial Fibrillation, Atrial Tachycardia
Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.
Catheter ablation of atrial fibrillation (AF) or left atrial tachycardia (GAD) is usually performed in patients treated with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) that are increasingly used.
- Trial name
- FACADO (NCT05802576)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation, Stroke
Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial…
- Trial name
- NCT02746107
- Testing
- decision aid
- Where
- Romania
- Volunteers
- 968 people
- Sponsor
- Cristian Baicus
Anticoagulant Therapy
Vitamin K for Perioperative Warfarin Management
This is a feasibility study of uninterrupted warfarin with a one time dose of Vitamin K before a surgical procedure.
- Trial name
- NCT07515664
- Testing
- Vitamin K, Warfarin (standard without loading), Warfarin (standard with loading)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Heart Disease, Stroke
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function.
- Conditions
- Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
- Trial name
- WARCEF (NCT00041938)
- Testing
- aspirin, Warfarin
- Where
- 64 sites in United States, Canada
- Volunteers
- 2,305 people
- Sponsor
- Columbia University
Cancer, Pulmonary Embolism
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of…
- Conditions
- Cancer, Pulmonary Embolism, Thrombosis
- Trial name
- CATforCAT (NCT06386107)
- Testing
- Thrombin Generation Assay (TGA)
- Where
- 4 sites in France
- Volunteers
- 212 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Stroke
Low-Molecular-Weight Heparin Injection in Stroke Patients
Bruising as a result of heparin injection increases patients' anxiety, decreases their confidence in the effectiveness of nurses and causes them to refuse the injection.
- Trial name
- NCT06076434
- Testing
- The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Kastamonu University
Superficial Thrombophlebitis
Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis
The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein…
- Trial name
- REVETR (NCT01245998)
- Testing
- Dalteparin
- Where
- Slovenia
- Volunteers
- 68 people
- Sponsor
- University Medical Centre Ljubljana
Atrial Fibrillation
Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial
Introduction: Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients.
- Trial name
- SILENT (NCT02004509)
- Testing
- Anticoagulant
- Where
- Brazil
- Volunteers
- 2,054 people
- Sponsor
- InCor Heart Institute
Thrombosis
Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula
Many guidelines at home and abroad advocate that arteriovenous fistula should be the first choice of permanent vascular access, but it is easy to form thrombus in a short time after arteriovenous fistula molding, resulting in…
- Trial name
- EASOAT (NCT04164693)
- Testing
- Low molecular weight heparin, non anticoagulant therapy group
- Where
- China
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
COVID-19
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes…
- Trial name
- NCT04828772
- Where
- 2 sites in Japan
- Volunteers
- 9,282 people
- Sponsor
- Bristol-Myers Squibb
Angina, Stable, Angina, Unstable
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher…
- Conditions
- Angina, Stable, Angina, Unstable, Anticoagulants
- Trial name
- COBRA-REDUCE (NCT02594501)
- Testing
- COBRA PzF, Drug Eluting Stent
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 996 people
- Sponsor
- CeloNova BioSciences, Inc.
Anticoagulant, Apixaban
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.
- Conditions
- Anticoagulant, Apixaban, Obesity
- Trial name
- NCT03893591
- Testing
- Anti Xa levels
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- HaEmek Medical Center, Israel
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Atrial Fibrillation
Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years
The objective of this study was to investigate whether there is a link between clinical and biological variables and bioassay high xaban in elderly patients as part of an unscheduled hospitalization.
- Trial name
- AOD-SA (NCT02894450)
- Testing
- blood test
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital